Drug Type Antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States | 21 Apr 2026 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States | 21 Apr 2026 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | Israel | 21 Apr 2026 |






